On Tuesday, Shares of Whiting Petroleum Corp (NYSE:WLL), subtract -2.98% and closed at $9.13 in the last trading session. The last trading range of the stock ranges between $9.02 and $9.44. The company’s Market capitalization is $2.62 Billion with the total Outstanding Shares of 275.40 million. During the 52-week trading session the minimum price at which share price traded, registered at $3.35 and reached to max level of $22.39. Whiting Petroleum Corporation (NYSE:WLL) will release its third quarter 2016 financial and operating results on Wednesday, October 26, 2016 after the market closes. A conference call with shareholders, analysts and other interested parties is planned for 11:00 a.m. EDT (10:00 a.m. CDT, 9:00 a.m. MDT) on Thursday, October 27, 2016 to discuss Whiting’s third quarter 2016 financial and operating results.
Mylan NV (NASDAQ:MYL), dropped -1.44% and closed at $38.31 in the last trading session. The last trading range of the stock ranges between $38.11 and $39.28. The company’s Market capitalization is $20.49 Billion with the total Outstanding Shares of 534.91 million. During the 52-week trading session the minimum price at which share price traded, registered at $35.58 and reached to max level of $55.51. Mylan N.V., together with its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream, or ointment forms, in addition to active pharmaceutical ingredients (APIs). It is also involved in the development of APIs with non-infringing processes for internal use and to partner with manufacturers; and manufacture and sale of injectable products in antineoplastics, anti-infectives, anesthesia/pain administration, and cardiovascular therapeutic areas. In addition, the company produces finished dosage form and oral solid dose products; and offers antiretroviral therapies to third parties. Further, it manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. It sells generic pharmaceutical products to proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies; and specialty pharmaceuticals to pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan N.V. has a partnershipagreement with Momenta Pharmaceuticals, Inc. to develop, manufacture, and commercialize Momenta Pharmaceuticals, Inc.s biosimilar candidates.